ZyVersa Therapeutics annual r&d spending
2022
2022
2023
2024
2025
ZyVersa Therapeutics R&D Spending Growth & History (ZVSA)
ZyVersa Therapeutics's r&d spending was $1.1M for fiscal 2025.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$666,170 | −37.44% |
| 2024 | 2024-12-31 | $1.8M | −$1.4M | −44.53% |
| 2023 | 2023-12-31 | $3.2M | — | — |
| 2022 | 2022-12-31 | $5.4M | — | — |
| 2022 | 2022-12-12 | $5.4M | — | — |
ZyVersa Therapeutics quarterly r&d spending
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $57,621 | −$201,255 | −77.74% |
| Q4 2025 | 2025-12-31 | $79,239 | −$42,007 | −34.65% |
| Q3 2025 | 2025-09-30 | $365,053 | −$70,990 | −16.28% |
| Q2 2025 | 2025-06-30 | $409,937 | −$299,112 | −42.18% |
| Q1 2025 | 2025-03-31 | $258,876 | −$254,061 | −49.53% |
| Q4 2024 | 2024-12-31 | $121,246 | −$135,865 | −52.84% |
| Q3 2024 | 2024-09-30 | $436,043 | −$237,900 | −35.30% |
| Q2 2024 | 2024-06-30 | $709,049 | −$511,527 | −41.91% |
| Q1 2024 | 2024-03-31 | $512,937 | −$543,006 | −51.42% |
| Q4 2023 | 2023-12-31 | $257,111 | — | — |
| Q3 2023 | 2023-09-30 | $673,943 | — | — |
| Q2 2023 | 2023-06-30 | $1.2M | — | — |
| Q1 2023 | 2023-03-31 | $1.1M | — | — |
ZyVersa Therapeutics r&d spending trends
Between the periods ended 2022-12-12 and 2025-12-31, ZyVersa Therapeutics's r&d spending decreased from $5.4M to $1.1M, a change of −$4.3M. The latest reported quarter, Q1 2026, shows $57,621.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗